RCS - Physiomics PLC - Physiomics to present at AACR Annual Meeting

PhysiomicsAnnouncement

14/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230414:nRSN1736Wa&default-theme=true

RNS Number : 1736W  Physiomics PLC  14 April 2023

14 April 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Conference presentation

 

Physiomics to present at AACR Annual Meeting

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, is pleased to announce that it is participating in the
American Association for Cancer Research Annual Meeting 2023, being held on
14-19 April 2023 in Orlando, FL.

 

The Company will give an oral presentation entitled "Development and
validation of a quantitative systems pharmacology model for prediction of
preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined
with the ATR inhibitor gartisertib (M4344)".  Physiomics is co-authoring the
presentation with client Merck KGaA.

 

This newly developed quantitative systems pharmacology model, part of our
Virtual Tumour platform, provides a framework that can be applied to optimise
the dosing regimens of PARP and ATR inhibitor combinations and help with
clinical dosing strategy.

 

The presentation will be given by Dr Nathalie Dupuy, Senior Biosimulation
Scientist, on 18 April 16:07-16:22 EDT (21:07-21:22 BST). The abstract (#5699)
is available at the conference website via this link
(https://www.abstractsonline.com/pp8/#!/10828/presentation/8054) . A copy of
the presentation will be posted on Physiomics' website at 17:00 EDT (22:00
BST) on the same day at: www.physiomics.co.uk/resources
(http://www.physiomics.co.uk/resources) .

 

More information about the conference may be found at:

www.aacr.org/meeting/aacr-annual-meeting-2023/
(http://www.aacr.org/meeting/aacr-annual-meeting-2023/)

 

Executive Chairman & CEO, Dr Jim Millen, said: "Being awarded a talk at a
high-profile conference such as AACR is a testimony to the scientific quality
of our team. We are excited to present publicly for the first time on our
collaborative work with Merck, and we are looking forward to meeting with
other attendees of the conference."

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUBWCUPWGAW